… Transduction of glia may be desirable for development of gene therapy-based treatments
for demyelinating diseases such as multiple sclerosis and Canavan disease. Under certain …

… Amyotrophic lateral sclerosis (… drug for the management of this disease, there is still no
definitive cure for it. In this regard, the use of mesenchymal stem cells (MSCs) for the treatment or …

… Currently, phase I clinical trial is being conducted on dose escalation study of autologous
MSCs in patients with Amyotrophic Lateral Sclerosis for determining the dose limiting toxicities […

… bench to the patient’s bedside, working on two types of drugs: antagomiRs and miRNA mimics.
The list of miRNA-based drugs in … processes in amyotrophic lateral sclerosis (ALS). In the …

… neurodegenerative disease treatment. Because of the fatal prognosis and imperative need
for effective treatment, amyotrophic lateral sclerosis (ALS) patients request this therapy before …

… drug from the bench to bedside is very expensive, laborious and slow process. The cost of
development and validation of potential therapeutic … with consecutive drug therapies until the …

… -type drugs will likely constitute the next generation of therapeutic agents for the treatment
of … common motor neuron disease, amyotrophic lateral sclerosis has already been reported […

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. It is
typically characterized by adult-onset degeneration of the upper and lower motor neurons, …

… basis for amyotrophic lateral sclerosis (ALS) has grown enormously. From these studies, it is
clear that defects in multiple … This example of bench to bedside drug development is a clear …

… States Food and Drug Administration (FDA) for treatment of amyotrophic lateral sclerosis (ALS), …
Is the Subject Area "Amyotrophic lateral sclerosis" applicable to this article? Yes No …